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Abstract
Purpose: We aimed to characterize the antiretroviral therapy (ART) cascade among female sex workers (FSWs) globally.
Methods: We systematically searched PubMed, Embase and MEDLINE in March 2014 to identify studies reporting on ART
uptake, attrition, adherence, and outcomes (viral suppression or CD4 count improvements) among HIV-infected FSWs
globally. When possible, available estimates were pooled using random effects meta-analyses (with heterogeneity assessed
using Cochran’s Q test and I2 statistic).
Results: 39 studies, reporting on 21 different FSW study populations in Asia, Africa, North America, South America, and
Central America and the Caribbean, were included. Current ART use among HIV-infected FSWs was 38% (95% CI: 29%–48%,
I2 = 96%, 15 studies), and estimates were similar between high-, and low- and middle-income countries. Ever ART use among
HIV-infected FSWs was greater in high-income countries (80%; 95% CI: 48%–94%, I2 = 70%, 2 studies) compared to low- and
middle-income countries (36%; 95% CI: 7%–81%, I2 = 99%, 3 studies). Loss to follow-up after ART initiation was 6% (95% CI:
3%–11%, I2 = 0%, 3 studies) and death after ART initiation was 6% (95% CI: 3%–11%, I2 = 0%, 3 studies). The fraction
adherent to $95% of prescribed pills was 76% (95% CI: 68%–83%, I2 = 36%, 4 studies), and 57% (95% CI: 46%–68%, I2 = 82%,
4 studies) of FSWs on ART were virally suppressed. Median gains in CD4 count after 6 to 36 months on ART, ranged between
103 and 241 cells/mm3 (4 studies).
Conclusions: Despite global increases in ART coverage, there is a concerning lack of published data on HIV treatment for
FSWs. Available data suggest that FSWs can achieve levels of ART uptake, retention, adherence, and treatment response
comparable to that seen among women in the general population, but these data are from only a few research settings.
More routine programme data on HIV treatment among FSWs across settings should be collected and disseminated.
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Introduction
By reducing HIV viral load and helping to restore immune
function, antiretroviral therapy (ART) has led to substantial
reductions in HIV-attributable mortality and morbidity and has
greatly improved the quality of life for people living with HIV.
Evidence also indicates that individuals on effective ART are less
likely to transmit HIV [1–5]. This evidence has sparked great
interest in ART-based HIV prevention approaches, including
‘Treatment as Prevention’ (TasP), which aims to expand ART
coverage among HIV-infected individuals in order to help reduce
HIV transmission at a population level [6].
Successful treatment can sustain viral suppression and lead to
immunological improvement among those that are HIV-infected,
but requires that individuals engage and remain in the HIV care
cascade. This cascade involves a series of actions, starting with
HIV screening/testing, and followed by linkage to HIV care after
HIV diagnosis, retention in pre-ART care prior to ART initiation,
initiation of ART once eligible for treatment, retention on
treatment once ART is started, and then maintenance of good
ART adherence in order to achieve viral suppression and
immunological improvement [7–9]. However, evidence indicates
that many individuals are lost at each stage of the cascade, and
many individuals are diagnosed late, only initiating ART at the
onset of symptoms [8–11].
Female sex workers (FSWs) are a population at high risk of
acquiring and transmitting HIV infection, and in many HIV
epidemics bear a disproportionately larger burden of HIV [12–
14]. Worldwide, the HIV prevalence among FSWs is 12%,
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ranging between 1.7% in the Middle East and North Africa to
36.9% in Sub-Saharan Africa, and FSWs have a pooled odds ratio
of HIV infection compared to women in the general population of
14 [13]. Thus, FSWs remain a key population for HIV prevention
strategies. Ensuring high levels of ART uptake, adherence and
retention among FSWs, would provide not only individual benefits
to HIV-infected FSWs, but could also help reduce HIV
transmission at the population level [15,16].
With the high burden of HIV among FSWs and the potential
merits of expanding ART in populations at high risk of
transmitting HIV [15,17], it is crucial to understand the extent
to which FSWs currently access ART, and continue ART with
good adherence. We conducted a systematic review to summarise
the existing information on the following events in the HIV care
cascade among FSWs globally: ART uptake, ART attrition,
adherence, and treatment response (viral suppression and CD4
count improvements).
Methods
Our systematic review and meta-analysis was conducted and
reported in accordance with PRISMA and MOOSE guidelines
(see Checklist S1) [18,19].
Search Strategy
Our search strategy was conducted in three stages. First, we
searched PubMed, Embase and MEDLINE for studies published
up until 10th March 2014. The search terms (keywords and
medical subject heading terms) reflected three key domains: HIV/
AIDS, FSWs and ART (see Table 1 for combinations of search
terms used). There were no language restrictions. Following
removal of duplicate references, abstracts were screened for
exclusion. If studies were not excluded after abstract screening, the
full text of the article was retrieved and evaluated for eligibility.
Second, we hand-searched the reference lists of all eligible studies
and relevant review articles identified in the database search for
additional publications. Finally, for completion, whenever an
eligible study analysed data from a specific FSW cohort, a
supplementary database search was conducted, using the name
and location of the FSW cohort and corresponding author names
as search terms, to find any additional publications. Authors were
contacted for additional information and supplementary data
when needed. One reviewer conducted the search, reviewed
abstracts, and evaluated full text articles for eligibility. Any queries
on article eligibility were discussed and resolved with other team
members.
Inclusion and Exclusion Criteria
We included observational or intervention studies with a sample
size of at least 10 FSWs that reported estimates or sufficient data to
derive the following ART cascade outcomes: ART uptake
(specifically the fraction of all HIV-infected individuals or the
fraction of all ART-eligible individuals, who either initiated ART
within a specified follow-up period, currently use ART, or ever
used ART (no time-frame for ART initiation specified)), ART
attrition (specifically the fraction using ART who were either lost-
to-follow-up, died or discontinued ART, or the fraction of
treatment-experienced individuals no longer on ART), ART
adherence (specifically the fraction achieving a predefined
threshold of adherence e.g. $90%, $95%, 100%), viral suppres-
sion (specifically the fraction with undetectable plasma viral load
following ART initiation), and CD4 counts at and/or after ART
initiation (specifically the median CD4 count, median CD4 count
gain, or fraction with CD4 counts ,200, 200–499 or .500 cells/
mm3). We included studies which reported on the same study
population if the studies provided estimates of different ART
cascade outcomes for that study population or provided estimates
for that study population on the same ART cascade outcome over
different time periods.
We included studies that enrolled active or former FSWs,
women who engage in sex work or transactional sex, or women
who exchange sex for money, drugs or gifts. ‘‘Active’’ FSWs were
defined as women who either reported sex work as their
employment at enrolment, or within the previous 6 months.
‘‘Former’’ FSWs were those that either reported sex work as a
former occupation at enrolment, reported transactional sex more
than 6 months ago, or were no longer sexually active. We excluded
review articles, mathematical modelling studies, qualitative studies
and conference/oral/poster abstracts.
Data Extraction
One reviewer extracted data from included articles, and any
queries during data extraction were discussed and resolved with
other team members. Variables extracted included study charac-
teristics (e.g. study design, study period and sample size of FSWs),
participant characteristics (e.g. HIV status and illicit drug use),
outcome estimates (or the data to calculate them), and the time
period over which estimates were measured. Exact binomial
confidence intervals (CI) for proportions were derived when not
provided. Each study could provide information on multiple ART
cascade outcomes and/or on the same ART cascade outcome over
different time periods. Multiple studies could provide different
ART cascade estimates for the same study population.
We also extracted information on ART initiation criteria and
ART administration in order to provide a background to the local
context for included studies. To assess risk of bias in included
Table 1. Search Terms Used For Search Strategy.
Domain Search Terms
HIV ‘‘HIV’’ OR ‘‘human immunodeficiency virus’’ OR ‘‘AIDS’’ OR ‘‘acquired immune deficiency syndrome’’
AND
FSWs ‘‘FSW’’ OR ‘‘FSWs’’ OR ‘‘CSW’’ OR ‘‘CSWs’’ OR ‘‘commercial sex’’ OR ‘‘female sex worker*’’ OR ‘‘commercial sex work*’’ OR ‘‘sex-work*’’ OR ‘‘sexwork*’’ OR
‘‘sex work*’’ OR ‘‘prostitute*’’ OR ‘‘prostitution’’ OR ‘‘transactional sex’’ OR ‘‘paid sex’’ OR ‘‘money for sex’’ OR ‘‘sex for money’’ OR ‘‘paid for sex’’ OR ‘‘sex
in exchange for money’’ OR ((‘‘core group’’ OR ‘‘high risk’’ OR ‘‘high-risk’’ OR highrisk’’) AND (‘‘female*’’ OR ‘‘women’’ or ‘‘woman’’))
AND
ART ‘‘ART’’ OR ‘‘antiretroviral*’’ OR ‘‘anti-retroviral*’’ OR ‘‘HAART’’ OR ‘‘highly active antiretroviral therapy’’ OR ‘‘cART’’ OR ‘‘combined antiretroviral therapy’’
doi:10.1371/journal.pone.0105645.t001
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studies, we also extracted the following study characteristics: study
setting and recruitment, type of sampling, and outcome measure-
ment methods. No studies were excluded from the systematic
review or meta-analysis on the basis of this assessment, but the
potential impact of these characteristics on study results was
considered when interpreting overall findings.
Data Analysis
We firstly describe key characteristics of all included studies and
the total number that provide estimates for the different ART
cascade outcomes. We then summarise the results from different
studies for each outcome. Given that several studies could provide
information on the same study population, we give both the
number of studies (Ns) and the number of independent study
populations (Np) when summarising the study characteristics and
ART cascade outcome estimates.
All available study estimates are presented on forest plots in the
main text and are also reported in Tables S1–S5. On all forest
plots, study estimates are grouped by country income (high-
income (HI) versus low- and middle-income (LMI)), and ordered
by study-period, follow-up period, or time on ART.
For each outcome with at least 2 study estimates available from
different study populations, we calculated an overall pooled
estimate, and when possible performed sub-group meta-analyses
by country income (i.e. HI versus LMI). These results are reported
in the main text and are also presented on forest plots. As time
period of data collection could influence HIV treatment outcomes,
in particular ART uptake outcomes, we did additional sub-group
analyses for ART uptake outcomes in order to address this issue. If
the time period of data collection for any estimates of ART uptake
spanned the pre-HAART and HAART era, sub-group meta-
analyses were performed if possible by year of data collection (i.e.
data collected in the pre-HAART to HAART era versus data
collected in the HAART era) for that ART uptake outcome.
These results are reported in the main text. We did not pool study
estimates for outcomes relating to median CD4 count. For all
other outcomes, we pooled study estimates using a DerSimonian
and Laird random effects model on the logit scale, and then back-
transformed the overall pooled estimate to the original scale. We
assessed heterogeneity across study-estimates using the Cochran Q
homogeneity test, which assesses whether differences in study
estimates are due to chance alone (typically a p-value ,0.1 or
,0.05 indicates heterogeneity between study estimates), and the I2
statistic, which measures the percentage of variation across study
estimates that is due to heterogeneity rather than chance (the
higher the I2 value the greater the heterogeneity between study
estimates) [20,21]. Meta-analyses were conducted using the ‘meta’
package in R (Version 3.0.0).
When pooling estimates, we only included study estimates with
sample sizes of at least 10 FSWs. Study estimates with an unknown
numerator and denominator were not included in any pooled
estimates, and for ART uptake outcomes any study estimates with
an unknown study period were not included in pooled estimates. If
a study provided estimates of an outcome over different time-
periods, we only used one estimate (the most recent estimate from
each study) for pooling. If more than one study reported estimates
of a given outcome for the same study population, we only used
one estimate per study population (the study estimate with the
largest sample size) for pooling. Study estimates that were included
in overall or subgroup pooled estimates are indicated in forest plots
and tables with a star symbol (*).
Results
Search Results and Study Characteristics
The search strategy and process of article selection is described
in Figure 1. Of 3081 unique publications identified in our original
search, 28 met the inclusion criteria (Figure 1). Additional studies
were then identified from the supplementary database search
(Ns = 9) and reference lists (Ns = 2) (Figure 1). In total, 39 studies
(Ns = 39) identified in the search were eligible to be included in our
review (Figure 1), providing data on 21 independent FSW study
populations (Np = 21) and at least 4,700 HIV-infected FSWs [22–
60]. Table 2 summarises the key characteristics of the 39 included
studies and their reported outcomes. Figure 2 shows the
geographical location of the study settings. Study characteristics
that were extracted to help assess risk of bias are shown in Table
S6.
The majority of the 39 included studies were prospective cohort
(Ns = 24, Np= 11) or cross-sectional (Ns =Np= 12) studies. There
were also a small number of intervention (Ns =Np= 2) and
retrospective case-control (Ns =Np= 1) studies. Twenty-four stud-
ies were conducted in five African countries: Benin (Ns =Np= 1),
Burkina Faso (Ns = 5, Np = 1), Kenya (Ns = 16, Np= 3), Rwanda
(Ns =Np= 1), and Zimbabwe (Ns = Np= 1). Six studies were
conducted in two North American countries: Canada (Ns = 4,
Np= 3) and United States (Ns =Np= 2). Six studies were
conducted in four Asian countries: India (Ns =Np= 3), Russia
(Ns =Np= 1), Thailand (Ns =Np= 1), and Vietnam (Ns =Np= 1).
Two studies were conducted in two Central America and
Caribbean countries: Dominican Republic (Ns =Np= 1), and El
Salvador (Ns =Np=1), and one study was conducted in South
America: Brazil (Ns =Np= 1). Twenty-four studies (62%) had
fewer than 150 HIV-infected FSW participants, and four studies
enrolled HIV-infected FSWs who were also injecting drug users
(IDUs) (Table 2).
Of the 39 eligible studies included, 26 reported ART uptake
outcomes, 10 reported ART attrition outcomes, 9 reported on
adherence to ART, 6 reported on viral suppression, and 17
reported on CD4 counts at and/or after ART initiation (Table 2
and Tables S1–S5). Criteria for ART initiation were reported by
only 16 studies, the majority of which reported a CD4 count
threshold for ART initiation of 200 cells/mm3 (Ns = 11) [28–
30,32,37–39,44,46,51,54]. Other CD4 count thresholds used for
ART initiation were CD4 count ,250 cells/mm3 (Ns = 2), CD4
count ,350 cells/mm3 (Ns = 1), and any CD4 count (Ns = 1)
[23,42,48,60], and in one other study the ART initiation criteria
changed from CD4 count ,200 cells/mm3 to CD4 count ,350
cells/mm3 during the study period (Ns = 1) [56]. Other details on
ART administration were provided in some studies. For example,
studies in Rwanda and India report that ART has been provided
free of charge to those with HIV through government ART
programmes and ART centres, since 2003 and 2004, respectively
[40,42,46]. Studies in Canada also report that ART is provided
free of charge through provincial drug treatment programmes,
and in the United States, free ART is provided to all those living
with HIV [23,45,48]. In 2005, an ART programme was initiated
in the Nairobi FSW cohort in Kenya, as part of the U.S. Presidents
Emergency Plan for AIDS Relief (PEPFAR), and FSWs received
ART through the research clinic [34]. From 2004, FSWs enrolled
in the Mombasa FSW cohort in Kenya received ART through
either the study research clinic or other clinics in the area, and
FSWs enrolled in the Ye´re´lon FSW cohort in Burkina Faso
received ART through either the study research clinic or the
Bobo-Dioulasso University Teaching Hospital [29,32,33,37–
39,49,51,54,56,57]. In another study in Mombasa, FSWs received
Antiretroviral Therapy in Female Sex Workers
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ART at the study research clinic, whilst in Benin FSWs accessed
ART at a medical center dedicated to FSWs [44,60].
ART Uptake
Estimates of ART uptake (either ART initiation within specified
follow-up periods, current ART use, or ever use of ART (no time-
frame for ART initiation specified)), among ART-eligible or all
HIV-infected FSWs, were available from 26 studies reporting on
20 independent study populations in Asia, Africa, North America,
South America, and Central America and the Caribbean
[22,24,32–34,36–38,40–43,45–50,52–55,57–60] (Figures 3, 4, 5,
Table S1). CD4 count criteria for ART initiation were reported by
only 8 of these studies (CD4 count #200 cells/mm3 (Ns = 5), CD4
count #250 cells/mm3 (Ns = 1), CD4 count ,350 cells/mm
3
(Ns = 1) and any CD4 count (Ns = 1)) (Table S1).
Estimates of ART initiation among all HIV-infected FSWs were
provided by 6 studies reporting on 4 independent study
populations in Asia and Africa (Ns = 6, Np= 4) (Figure 3A, Table
S1A). Across these 6 studies, 0.4% to 48% of HIV-infected FSWs
initiated ART, during follow-up periods which varied between 4
months to 16 years (Ns = 6, Np= 4) (Figure 3A, Table S1A). The
overall pooled estimate for ART initiation among HIV-infected
FSWs, when pooling only one estimate per study population, was
19% (95%CI: 10%–35%, I2 = 96%, Ns =Np=4) (Figure 3A).
Pooled estimates were lower for studies which collected data on
HIV-infected FSWs between the pre-HAART and HAART era
(6%; 95%CI: 0%–51%, I2 = 96%, Ns =Np=2) than for studies
which collected data on HIV-infected FSWs in the HAART era
alone (37%; 95%CI: 20%–58%, I2 = 91%, Ns =Np= 2).
One study in Rwanda provided estimates of ART initiation
among ART-eligible FSWs (Figure 3B, Table S1B). In this study,
Figure 1. Flow diagram of search strategy and study selection process. FSW = female sex worker, ART = antiretroviral therapy, Ns =
number of studies.
doi:10.1371/journal.pone.0105645.g001
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87% of ART-eligible (CD4 ,350 cells/mm3) FSWs enrolled in
HIV care reported initiating ART within 12 to 36 months of their
HIV diagnosis [42] (Figure 3B, Table S1B).
Estimates of current ART use among all HIV-infected FSWs
were provided by 18 studies reporting on 16 independent study
populations in Asia, Africa, North America, South America, and
Central America and the Caribbean (Ns = 18, Np = 16) (Figure 4,
Table S1A). Across these 18 studies, the fraction of HIV-infected
FSWs currently using ART ranged between 0% and 72%
(Ns = 18, Np= 16) (Figure 4, Table S1A). The overall pooled
estimate for current ART use among HIV-infected FSWs, when
pooling only one estimate per study population and pooling only
those estimates with a known time period of data collection
measured among at least 10 FSWs, was 38% (95% CI: 29%–48%,
I2 = 96%, Ns =Np= 15) (Figure 4). Pooled estimates were similar
for LMI countries (39%; 95% CI: 27%–53%, I2 = 97%,
Ns =Np= 9) and HI countries (35%; 95% CI: 20%–55%,
I2 = 87%, Ns =Np=6) (Figure 4). Removing the one LMI country
estimate where data on HIV-infected FSWs was collected between
the pre-HAART and HAART era had a marginal impact on the
pooled estimate for LMI countries (42%; 95% CI: 29%–57%,
I2 = 97%, Ns =Np=8).
Estimates of ever ART use (i.e. no time-frame for ART
initiation specified) among HIV-infected FSWs were provided by
five studies reporting on 5 independent study populations in Asia,
Africa, North America, and Central America and the Caribbean.
Across these 5 studies, the fraction of HIV-infected FSWs who had
ever used ART ranged between 14% and 91% (Ns =Np= 5)
(Figure 5, Table S1A). The overall pooled estimate of ever ART
use among HIV-infected FSWs was 54% (95% CI: 21%–84%,
I2 = 98%, Ns =Np= 5). Pooled estimates were lower for LMI
countries (36%; 95% CI: 7%–81%, I2 = 99%, Ns =Np= 3) than
HI countries (80%; 95% CI: 48%–94%, I2 = 70%, Ns =Np= 2)
(Figure 5).
Treatment Attrition
Estimates of treatment attrition (either treatment discontinua-
tion, loss-to-follow-up on ART, death on ART, or ART-
experienced but no longer on ART), were available from 10
studies reporting on 6 independent study populations in Africa,
North America, and Central America and the Caribbean
[24,25,28,29,38,39,48,51,53,60] (Figure 6, Table S2).
Treatment discontinuation was reported by 2 studies reporting
on the same study population in Kenya (Ns = 2, Np = 1)
(Figure 6A, Table S2). In this Kenyan cohort, estimates of
treatment discontinuation among FSWs starting ART, increased
from 4% at 6 months to 10% at 12 months [28,29] (Figure 6A,
Table S2).
Estimates of loss-to-follow-up among FSWs on ART were
provided by 6 studies reporting on 3 independent study
populations in Kenya and Burkina Faso (Ns = 6, Np= 3)
(Figure 6B, Table S2). Across the three different study popula-
tions, estimates of loss-to-follow-up after ART initiation were
similar, ranging between 3% and 10% after varying times on ART
(Ns = 6, Np= 3) (Figure 6B, Table S2). In one of the Kenyan
cohorts, loss-to-follow-up increased from 3% after 3 months to 6%
after 12 months on ART [28,29], whilst in the Burkina Faso
cohort 4% were lost-to-follow-up after 32 months on ART
[38,39]. The overall pooled estimate of loss-to-follow-up on ART,
when pooling the most recent study estimate per study population,
was 6% (95% CI: 3%–11%, I2 = 0%, Ns =Np= 3) (Figure 6B).
Estimates of death among FSWs on ART were provided by 6
studies reporting on 3 independent study populations in Kenya
and Burkina Faso (Ns = 6, Np= 3) (Figure 6C, Table S2). Across
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the three different study populations, the fraction of FSWs who
died after varying times on ART ranged between 0% and 8.5%
(Ns = 6, Np= 3) (Figure 6C, Table S2). In two of the study
populations in Kenya and Burkina Faso the fraction of FSWs who
died whilst on ART increased over time [28,29,38,39,51]
(Figure 6C, Table S2). The overall pooled estimate of death on
ART, when pooling the most recent study estimate per study
population, was 6% (95% CI: 3%–11%, I2 = 0%, Ns =Np= 3)
(Figure 6C). In one of the Kenyan cohorts, total attrition from
ART, due to treatment discontinuation, loss-to-follow-up and
Figure 2. Map of Study Locations. Red dots highlight the countries where included studies were conducted.
doi:10.1371/journal.pone.0105645.g002
Figure 3. Forest plot of ART initiation among (A) all HIV-infected FSWs and (B) all ART-eligible FSWs. Study estimates are grouped by
country income and ordered by follow-up period. The star symbol (*) highlights the individual study estimates (one per study population) included in
the pooled overall estimate. I2 and p-values are the measures of heterogeneity used. a ART was provided to FSWs in the Kenyan cohort from 2004, b
Follow-up refers to months since HIV-diagnosis, study recruitment occurred between 1993 and 2009, c Follow-up refers to months since HIV-
diagnosis, study recruitment occurred between 2006 and 2008. d N refers to HIV-infected ART-eligible FSWs who had enrolled in HIV care following
HIV diagnosis. ART = antiretroviral therapy, FSW = female sex workers, CI = confidence interval, n = number of FSWs with each outcome, N=
sample size of FSWs available for each outcome, Np = number of independent study populations.
doi:10.1371/journal.pone.0105645.g003
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mortality, was 10% and 21%, after 6 and 12 months on ART,
respectively [28,29].
Estimates of the number of treatment-experienced FSWs that
reported no longer receiving ART, were provided by 3 studies
reporting on 3 independent study populations in Canada, USA
and Dominican Republic (Ns = 3, Np= 3) (Figure 6D, Table S2).
Across these three studies, the fraction of treatment-experienced
FSWs that reported no longer receiving ART ranged between 8%
and 47%, with an overall pooled estimate of 26% (95% CI: 6%–
65%, I2 = 93.3%, Ns =Np=3) (Figure 6D). The pooled estimate
for HI countries (43%; 95% CI: 29%–58%, I2 = 0%, Ns =Np=2),
was higher than the single LMI country estimate (8%, 95% CI:
4%–12%, Ns =Np=1) (Figure 6D, Table S2).
Adherence
Estimates of adherence (i.e. the fraction achieving a predefined
threshold of adherence) were available from 9 studies, reporting on
7 independent study population in Africa, North America, and
Central America and the Caribbean [23,25,30,38,39,42,48,53,60]
(Figure 7, Table S3). Among these 9 studies, three reported the
availability of adherence counselling [23,38,39], one study
reported the use of directly observed therapy [30], and one study
reported that monthly support groups were used to promote
adherence [60] (Table S3). The fraction of FSWs adherent to
treatment was consistently high, ranging from 67% to 100%
(Ns = 9, Np= 7), across the varying time periods, adherence
thresholds ($90%, $95% and 100%), recall periods (past 3 days,
past 4 days, past week, past 30 days, past month, and since ART
initiation), and methods of assessment (self-report, pill count and
visual analog scale) (Figure 7, Table S3). Estimates of the fraction
of FSWs 100% adherent to ART were highest shortly after starting
directly observed therapy (91% after 28 days on ART [30]) and at
the end of a peer-driven intervention (90.4% [23]) (Figure 7,
Table S3). Estimates of the fraction of FSWs $95% adherent to
ART increased from 83% after 6 months on ART to 100% after
36 months on ART in a cohort in Burkina Faso [38,39] (Figure 7,
Table S3). For LMI countries, the pooled estimate of adherence,
when pooling only one estimate per study population and pooling
only those estimates with a known numerator and denominator,
was 76% (95% CI: 68%–83%, I2 = 36%, Ns =Np=4) (Figure 7).
Viral Suppression
Estimates of viral suppression (i.e. the fraction on ART with
undetectable plasma viral load), were available from 6 studies
Figure 4. Forest plot of current ART use among HIV-infected FSWs. Study estimates are grouped by country income and ordered by study-
period. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall or subgroup estimates. Only
study estimates with a known time period of data collection which were measured among at least 10 FSWs were used for pooling. I2 and p-values are
the measures of heterogeneity used. a ART was provided to FSWs in the Kenyan cohort from 2004, b Sample is ‘active’ FSWs, c Sample is ‘active’ and
‘former’ FSWs. ART = antiretroviral therapy, FSW = female sex workers, CI = confidence interval, NR = not reported, n = number of FSWs with each
outcome, N= sample size of FSWs available for each outcome, Np = number of independent study populations.
doi:10.1371/journal.pone.0105645.g004
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reporting on 4 independent study populations in Asia, Africa, and
Central America and the Caribbean [28,38,39,43,53,56] (Fig-
ure 8, Table S4). The fraction of FSWs on ART virally
suppressed, ranged between 40%–82% (Ns = 6, Np= 4), across
varying time periods and definitions of viral suppression (#50
copies/mm3, #100 copies/mm3, #180 copies/mm3, #300
copies/mm3) (Figure 8, Table S4). The lowest study estimate of
viral suppression (40%) was reported in the Kenyan study
population after 3 months on ART [28], which increased to
73% after 6 months on ART [28] (Figure 8, Table S4). In the
Burkina Faso study population, the high fraction of FSWs virally
suppressed (79%–88%) after 6 to 36 months on ART, corre-
sponded to similarly high levels of treatment adherence seen over
the same time periods for these FSWs (Figure 7 & 8, Tables S3 &
S4) [38,39]. The overall pooled estimate of viral suppression, when
pooling one estimate per study population, was 57% (95% CI:
46%–68%, I2 = 82%, Ns =Np= 4) (Figure 8).
CD4 Counts at and/or after ART Initiation
Information on CD4 counts at and/or after ART initiation
(either median CD4 count, median CD4 count gain, or fraction
with CD4 counts .500, 200–499 or ,200 cells/mm3), were
available from 17 studies reporting on 5 independent study
populations in Africa [25–32,34,35,37–39,42,44,51,56] (Figures 9
&10, Table S5). Across the studies, the CD4 count criteria for
ART initiation was either #200 cells/mm3 or not reported, with
one study reporting a change in ART initiation criteria from CD4
count,200 cells/mm3 to CD4 count,350 cells/mm3 (Table S5).
Median CD4 counts at and/or after ART initiation were
provided by 14 studies reporting on 5 independent study
populations in Benin, Kenya, Burkina Faso, and Rwanda
(Ns = 14, Np = 5) (Figure 9A & 9B, Table S5A). Across 4 of these
study populations, the median CD4 count ranged between 121
and 205 cells/mm3 at ART initiation (Ns = 12, Np= 4), and 204 to
343 cells/mm3 after 1 to 36 months on ART (Ns = 9, Np= 4)
(Figure 9A & 9B, Table S5A).
Median gains in CD4 count following ART initiation, were
provided by 5 studies reporting on 4 independent study
populations in Benin, Kenya, Burkina Faso, and Rwanda
(Ns = 5, Np= 4) (Figure 9C, Table S5A). Across 3 of these study
populations, median gains in CD4 counts after 6 to 36 months on
ART, ranged between 103 and 241 cells/mm3 (Ns = 4, Np= 3)
(Figure 9C, Table S5A).
Estimates of the fraction of FSWs with CD4 counts ,200, 200–
499 or .500 cells/mm3 at and/or after ART initiation were
provided by 2 studies reporting on 2 independent study
populations in Kenya and Burkina Faso (Ns = 2, Np= 2)
(Figure 10, Table S5B). In the Kenyan study, the fraction of
FSWs with CD4 counts #200 cells/mm3, decreased from 90% at
ART initiation to 11% after 24 months on ART [32] (Figure 10A,
Table S5B). When pooling the most recent study estimates from
the 2 study populations, the overall pooled fractions of FSWs on
ART with CD4 counts,200 cells/mm3, 200–499 cells/mm3, and
.500 cells/mm3, were 22% (95% CI: 5%–66%, I2 = 88%,
Ns =Np= 2), 63% (95% CI: 28%–89%, I
2 = 89%, Ns =Np= 2),
and 13% (95% CI: 7%–22%, I2 = 0%, Ns =Np= 2), respectively
[32,37] (Figure 10).
Discussion
Despite the recent momentum to scale-up ART coverage
worldwide, there is a concerning lack of published data on HIV
treatment among FSWs [61]. We found only thirty-nine studies,
from fourteen different countries in Africa, Asia, North America,
South America, and Central America and the Caribbean that
reported information on the ART cascade among FSWs
(Figure 2). Of these studies, the majority reported estimates of
either current ART use or median CD4 counts at and/or after
Figure 5. Forest plot of ever ART use among HIV-infected FSWs. Study estimates are grouped by country income and ordered by time-
period. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall or subgroup estimates. I2 and p-
values are the measures of heterogeneity used. a Sample is ‘active’ FSWs, b Sample is ‘active’ and ‘former’ FSWs. ART = antiretroviral therapy, FSW =
female sex workers, CI = confidence interval, n = number of FSWs with each outcome, N= sample size of FSWs available for each outcome, Np =
number of independent study populations.
doi:10.1371/journal.pone.0105645.g005
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ART initiation, with very few providing estimates of treatment
attrition, adherence and viral suppression among FSWs.
ART uptake among HIV-infected FSWs was particularly
variable across the different studies and settings. Pooled estimates
of ART initiation in HIV-infected FSWs were higher among
studies which collected data on HIV-infected FSWs exclusively in
the HAART era versus studies which collected data spanning the
pre-HAART and HAART eras, and pooled estimates of ever
Figure 6. Forest plot of treatment attrition among HIV-infected FSWs, including (A) treatment discontinuation (B) loss to follow-up
on ART (C) death on ART and (D) ART-experienced but no longer on ART. Study estimates are grouped by country income and ordered by
time on ART. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall or subgroup estimates. For
studies providing estimates over multiple time-periods, only one estimate was used for pooling (the most recent estimate from that study). I2 and p-
values are the measures of heterogeneity used. ART = antiretroviral therapy, FSW = female sex workers, CI = confidence interval, NR = not
reported, n = number of FSWs with each outcome, N= sample size of FSWs available for each outcome, Np = number of independent study
populations, m= median, LFU = lost to follow-up.
doi:10.1371/journal.pone.0105645.g006
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ART use among HIV-infected FSWs were higher in high-income
countries compared to low- and middle-income countries.
Conversely, pooled estimates of current ART use among HIV-
infected FSWs were similar between high-income countries and
low- and middle-income countries. However, there was substantial
between-study heterogeneity for all pooled estimates of ART
uptake. Varied study periods, different follow-up times and
different ART eligibility criteria across studies could all contribute
to the variability in study estimates. Nevertheless, pooled estimates
of current ART use among HIV-infected FSWs are similar to
estimates of current ART use among HIV-infected women in
Burkina Faso (27%) and among HIV-infected female IDUs in
Canada (30%) [62,63]. Likewise, in the one study in Rwanda that
reported ART initiation among ART-eligible FSWs, the propor-
Figure 7. Forest plot of ART adherence among HIV-infected FSWs. Study estimates are grouped by country income and ordered by time on
ART. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall or subgroup estimates. Only study
estimates with a known sample size of at least 10 FSWs were used for pooling. For studies providing estimates over multiple time-periods, only one
estimate was used for pooling (the most recent estimate from that study). I2 and p-values are the measures of heterogeneity used. ART =
antiretroviral, FSW = female sex workers, CI = confidence interval, NR = not reported, n = number of FSWs with each outcome, N= sample size
of FSWs available for each outcome, Np = number of independent study populations, m= median, PDI = peer driven intervention, PC = pill count,
SR = self-report, VAS = visual analog scale.
doi:10.1371/journal.pone.0105645.g007
Figure 8. Forest plot of viral suppression among HIV-infected FSWs on ART. Study estimates are grouped by country income and ordered
by time on ART. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall estimate. For studies
providing estimates over multiple time-periods, only one estimate was used for pooling (the most recent estimate from that study). I2 and p-values
are the measures of heterogeneity used. ART = antiretroviral, FSW = female sex workers, CI = confidence interval, NR = not reported, n = number
of FSWs with each outcome, N= sample size of FSWs available for each outcome, Np = number of independent study populations, m= median.
doi:10.1371/journal.pone.0105645.g008
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tion of ART-eligible FSWs in HIV care initiating ART was similar
to the proportion of ART-eligible individuals in the Rwandan
general population initiating ART (71%) [42].
Data from two African FSW research cohorts suggest that
treatment discontinuation, loss to follow-up on ART, and
mortality on ART among FSWs may be low, at least over the
first few years of ART use [25,28,29,38,39]. However, these
studies were conducted in research contexts where there is likely to
be intensive follow-up of participants, and thus better retention on
treatment. Even so, total treatment attrition after one year on
ART in one of the African FSW cohorts was similar to that found
in the sub-Saharan African general population after 12 months on
ART (23%) [64]. In addition estimates of loss to follow-up and
death on ART among FSWs are similar to if not better than
estimates of loss to follow-up and death among women on ART
enrolled in cohort studies in South Africa and Tanzania, where
17.5% and 25.6% were loss to follow-up, respectively, and 4.1%
and 12.8% died on ART, respectively [65,66]. Only three studies
in Dominican Republic, Canada and the USA reported on the
fraction of ART-experienced FSWs that were no longer on ART,
and there was substantial between-study heterogeneity. Although
the proportion of FSWs in the Dominican Republic that reported
ever but not current ART use was similar to that reported by
women from the general population in the USA (9%) [67], the two
cross-sectional studies in North America found much higher
proportions of FSWs self-reporting that they were previously but
no longer on ART [24,48]. However, the sample size of FSWs in
these two North American studies was very small.
Figure 9. Forest plot of (A) median CD4 count and (B) median gains in CD4 count among HIV-infected FSWs on ART and starting
ART. Study estimates are grouped by country income and ordered by time on ART. a N refers to a subset of FSWs who were eligible for ART upon HIV
diagnosis and enrolled in HIV care following HIV diagnosis. ART = antiretroviral, FSW = female sex workers, CI = confidence interval, NR = not
reported, N= sample size of FSWs available for each outcome, Np = number of independent study populations, m= median, IQR = interquartile
range.
doi:10.1371/journal.pone.0105645.g009
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Adherence among FSWs, in the few studies where it was
measured, was found to be consistently high despite different
methods of assessment, recall periods and adherence thresholds.
The pooled estimate of adherence among FSWs is similar to that
reported for the general population in sub-Saharan Africa, where
77% were estimated to be $80% adherent [68], and is also similar
to if not better than that reported for women in the general
population, where 62% were estimated to be $90% adherent
[69]. Adherence counselling in 4 studies [23,38,39,44], monthly
support groups in one study [60], and directly administered
therapy in another study [30], could have contributed to the high
adherence seen in these FSW study populations.
Limited data also indicate that overall just over half of FSWs
initiating ART are achieving viral suppression, which is much
lower than the pooled estimate of ART adherence seen among
FSWs. However, there was considerable between-study heteroge-
neity in the pooled estimate of viral suppression, and the varied
limits of viral load detection used to define viral suppression, which
Figure 10. Forest plot of the fraction of HIV-infected FSWs on ART and starting ART with (A) CD4 counts ,200 cells/mm3 (B) CD4
counts 200–499 cells/mm3 and (C) CD4 counts .500 cells/mm3. Study estimates are grouped by country income and ordered by time on
ART. The star symbol (*) highlights the study estimates (one per study population) included in the pooled overall estimates. For studies providing
estimates over multiple time-periods, only one estimate was used for pooling (the most recent estimate from that study). I2 and p-values are the
measures of heterogeneity used. a ART initiation criteria is CD4 count ,200 cells/mm3. ART = antiretroviral, FSW = female sex workers, CI =
confidence interval, NR = not reported, n = number of FSWs with each outcome, N= sample size of FSWs available for each outcome, Np = number
of independent study populations.
doi:10.1371/journal.pone.0105645.g010
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ranged from ,50 copies/ml to ,300 copies/ml, may have
influenced the results. The cohort of FSWs in Burkina Faso which
used the highest limit of viral load detection to define viral
suppression (,300 copies/ml), had the highest estimates of viral
suppression, and these were comparable to estimates of viral
suppression (defined as viral load ,400 copies/ml) seen among
women from the general population in South Africa, where 87%–
93% of women were virally suppressed after 12 to 36 months on
ART [70]. The FSWs in Burkina Faso, who had the highest levels
of viral suppression, also had high levels of adherence [38,39].
Thus, the lower estimates of viral suppression could also reflect
lower adherence rates among FSWs in those study settings.
For a number of FSWs, improvements in CD4 count were also
achieved within 6 to 24 months of ART initiation, and these were
comparable to the median gains in CD4 count achieved among
women in the general population from South Africa and the UK
after 6 to 12 months on ART [70,71].
To date, this is the first study to systematically review and
quantify the ART cascade among FSWs globally, which builds on
a limited review already undertaken by the authors [15]. Available
data indicate that FSWs can achieve promising levels of ART
uptake, adherence, retention, and treatment response, at least in
the short-term and in these research settings, which in some cases
may even be comparable to that seen in the general population
over similar time-periods. However, there are a number of
limitations to this systematic review. In particular, the review and
meta-analysis were limited by the scarcity and heterogeneity of
eligible studies. The included studies, the majority of which had
small sample sizes of HIV-infected FSWs, reported data on only
twenty-one different FSW study populations from only fourteen
countries in Asia, Africa, North America, South America, and
Central America and the Caribbean, which limits the generaliz-
ability of these findings to FSWs elsewhere (Figure 2). Most of the
included studies were also research cohorts, thus these results are
of limited generalizability to FSWs in other routine programme
(non-research) settings. FSWs enrolling in research cohorts may be
more motivated to adhere to and remain on treatment, and there
are likely to be a number of other HIV prevention and support
services available to FSWs in these cohorts, which coupled with
intense follow-up and intensive adherence counselling, could help
to improve ART uptake, retention, adherence and treatment
outcomes among FSWs in these studies [72,73]. Our pooled
analyses are also limited by the heterogeneity between studies, but
still provide useful overall estimates of engagement in HIV
treatment among FSWs. Study periods were particularly variable
across studies, and this is likely to influence HIV treatment
outcomes, in particular ART uptake. The time periods of data
collection spanned 24 years across the different study settings, and
in some studies collection of data on HIV-infected FSWs started in
the pre-HAART era. To address this issue, whenever possible we
conducted sub-group analyses for ART uptake outcomes by time-
period of data collection (i.e. data collected in the pre-HAART to
HAART era versus HAART era alone). We found that this had an
effect on pooled estimates of ART initiation, and although
substantial between-study heterogeneity remained, this could
indicate that it might not be appropriate to aggregate all data
on ART uptake regardless of study period. In the majority of
cohort studies, follow-up time on ART was also relatively short, so
long term attrition and treatment outcomes in FSWs remain
unknown. Lack of reporting on local ART eligibility criteria also
made it more difficult to interpret estimates of ART uptake. In
addition, adherence to medication was most frequently measured
by either self-reports or pill counts, both of which are prone to
biases, such as social desirability and recall bias (Table S6).
Different types of recruitment settings and sampling methods may
have also introduced selection bias into the included studies.
However, it was difficult to fully assess risk of selection bias as very
few studies reported sampling methodology (Table S6). Some
studies reported using random samples, whilst a few others
reported the use of non-probability sampling methods, such as
snowball sampling and convenience sampling. Snowball sampling
and convenience sampling are commonly used when studying
hard-to-reach populations, but are likely to have introduced bias
into the selection of participants [74]. A couple of studies also
reported the use of respondent-driven sampling, which is a type of
snowball sampling that aims to reduce bias by taking into account
the non-random patterns of participant recruitment [74]. The
different recruitment settings and strategies also highlight the
diversity of FSW samples across studies (Table S6). Pooled
estimates may mask the potential differences in HIV treatment
and care across the varied contexts and settings of sex work. It is
also possible that women who do not self-identify as FSWs may
have been missed at study recruitment, so in some cases outcome
data is likely to be restricted to self-identifying FSWs. Thus, results
may not be generalizable to indirect FSWs, who may not have
been captured in these samples. Publication bias may have also
affected our summary estimates, but due to the small numbers of
studies that reported each outcome we could not explore this in a
meaningful way. In addition, as we did not search for available
data in the grey literature (our review focussed on peer-reviewed
published literature), we have likely excluded some ART data that
may have been available, for example, from reports of integrated
biological and behavioural assessment (IBBA) surveys among
FSWs.
Despite the limitations, the results from this review are
encouraging, and show that even though FSWs are considered a
hard population to reach for HIV prevention and care, research
cohorts in particular have achieved success at enrolling and
retaining FSWs on ART with good adherence and treatment
response. Importantly, this review also has important public health
implications since it highlights large gaps in the spatial distribution
of ART cascade estimates among FSWs (Figure 2) and the paucity
of data on the ART cascade among FSWs in routine (non-
research) programme settings. These data gaps are concerning,
and impede our understanding of ‘real-life’ HIV treatment and
care among FSWs and potential feasibility and effectiveness of
targeting FSWs for expanded ART prevention strategies. It is
crucial that routine programme data on HIV care and treatment
among FSWs is collected and disseminated, in order to better
characterise ART cascade outcomes among FSWs (see Box S1 for
a summary of our recommendations for future data collection). In
particular, information on the percentage of all HIV-infected
FSWs receiving ART, and how this evolves over time is needed.
Estimates of ART use are likely to be affected by ART initiation
criteria, HIV testing policies and testing uptake, as well as rates of
linkage to and retention in HIV care prior to ART initiation. So in
order to interpret data on ART uptake among FSWs, information
on the evolution of ART eligibility criteria over time, the CD4
count at which FSWs are diagnosed and started treatment, as well
as the percentage of HIV-infected FSWs who receive HIV testing
and are linked to HIV care is required. Furthermore, gathering
additional short and long-term data on treatment retention,
adherence and viral suppression among FSWs, using standardised
indicators is crucial. In 2010, the WHO recommended a number
of different early warning indicators to use for monitoring of HIV
drug resistance in national ART programmes, which included the
following ART care indicators: % of patients receiving ART lost to
follow-up at 12 month, % of patients retained on first-line ART at
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12 months, % of patients with 100% on-time drug pickups during
the first 12 months of ART or during a specified time period, %
patient adherence to antiretroviral therapy by pill count or other
standardized measure, and % of patients with viral load ,1000
copies/mm3 at 12 months [75]. Gathering and reporting data on
these types of ART care indicators for sex workers in routine
surveys of sex workers, existing sex worker programmes, and new
research studies of HIV care and treatment among FSWs, could
help to better characterise the ART cascade among FSWs in
different settings and contexts.
When scaling up ART programmes for FSWs, it will also be
important to elucidate and overcome the barriers that FSWs face
to initiating ART, remaining on treatment and adhering to ART.
Many individual-level and structural-level barriers, such as stigma,
discrimination, violence, and drug-use, often prevent FSWs from
accessing HIV services and practicing HIV prevention and harm
reduction, and these barriers may also influence the ability of
FSWs to traverse through the HIV care cascade [76–79]. In two of
the studies included in this systematic review, FSWs reported that
inability to attend regular medical appointments, potential loss of
wages from visiting ART centres, prior negative experiences with
the health care system, the stigmatizing attitude of medical staff,
and fear of adverse consequences as a result of others knowing
their HIV status and occupation, were some of the factors that
prevented them from initiating ART [24,46]. In three of the
studies included in this systematic review, FSWs also reported that
running out of pills, not being at home to take pills, feelings of
sickness when taking pills, and potential loss of clients if seen taking
ART during work hours, were factors that prevented them from
adhering to treatment [42,44,46]. Another qualitative study
among FSWs in Zimbabwe also found that discrimination from
medical staff, shame, and anxiety about being known to be a sex
worker, reduced the ability of FSWs to attend HIV treatment
services [80]. Travelling times to health clinics and additional
financial costs were also reported as barriers to treatment [80]. It is
essential that new or ongoing HIV intervention and ART
programmes among FSWs try to address the structural and social
barriers to HIV treatment that FSWs’ face. For example, Abriendo
Puertas, is an ongoing integrated HIV care and prevention
intervention for FSWs in Dominican Republic, that aims to
promote HIV care and preventative behaviours among FSWs
[53]. This intervention has four key components, including
individual counselling and education, peer HIV service navigation
and support, clinical care health provider sensitisation training,
and community solidarity and mobilisation, which together aim to
provide a multi-level response to the social and structural factors
that prevent FSWs engaging and remaining in care and adhering
to treatment [53]. In Zimbabwe, the Sisters with a Voice (SWV)
programme, which provides free STI/HIV services and assisted
referrals to ART centers for FSWs, has also initiated numerous
measures to try and reduce the stigma, discrimination and barriers
that FSWs face at public health clinics, including training and
sensitisation for nurses at public ART centers and community
mobilisation among FSWs [80].
In conclusion, existing studies in a limited number of research
settings indicate that it is it is feasible to enrol and retain FSWs on
ART with good adherence, at least in the short-term and in these
research contexts. However, there is an evident gap in global data
on ART cascade outcomes among FSWs. More data, particularly
long-term data, from a larger number of FSW study populations
and non-research settings, needs to be collected and disseminated.
When scaling-up ART programmes for FSWs, the barriers to HIV
care and treatment that they face also need to be addressed.
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